ATE321131T1 - Mutierte klasse-i-mhc-moleküle - Google Patents

Mutierte klasse-i-mhc-moleküle

Info

Publication number
ATE321131T1
ATE321131T1 AT98942169T AT98942169T ATE321131T1 AT E321131 T1 ATE321131 T1 AT E321131T1 AT 98942169 T AT98942169 T AT 98942169T AT 98942169 T AT98942169 T AT 98942169T AT E321131 T1 ATE321131 T1 AT E321131T1
Authority
AT
Austria
Prior art keywords
mhc molecules
mutated class
class
mutated
beta2
Prior art date
Application number
AT98942169T
Other languages
English (en)
Inventor
David N Garboczi
Juergen B Walter
Original Assignee
David N Garboczi
Juergen B Walter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David N Garboczi, Juergen B Walter filed Critical David N Garboczi
Application granted granted Critical
Publication of ATE321131T1 publication Critical patent/ATE321131T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Removal Of Specific Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98942169T 1997-08-29 1998-08-20 Mutierte klasse-i-mhc-moleküle ATE321131T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/920,413 US6248564B1 (en) 1997-08-29 1997-08-29 Mutant MHC class I molecules

Publications (1)

Publication Number Publication Date
ATE321131T1 true ATE321131T1 (de) 2006-04-15

Family

ID=25443710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942169T ATE321131T1 (de) 1997-08-29 1998-08-20 Mutierte klasse-i-mhc-moleküle

Country Status (5)

Country Link
US (1) US6248564B1 (de)
EP (1) EP1017799B1 (de)
AT (1) ATE321131T1 (de)
DE (1) DE69833949T2 (de)
WO (1) WO1999011775A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US20040209314A1 (en) 1999-09-06 2004-10-21 Institut National De La Sante Et De La Recherche Medicale France Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA
FR2798128B1 (fr) * 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
AU785493B2 (en) * 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
AU2003284162A1 (en) * 2002-10-28 2004-05-25 Genzyme Corporation Anti-hiv (sl9) compounds
WO2004078137A2 (en) * 2003-03-04 2004-09-16 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) * 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
EP2007428A2 (de) 2006-04-05 2008-12-31 Genentech, Inc. Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
ES2549128T3 (es) * 2006-05-19 2015-10-23 Technion Research And Development Foundation Ltd. Proteínas de fusión, usos de las mismas y procesos para producir las mismas
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
WO2008076933A2 (en) * 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
CA2678618C (en) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
EP2361930A3 (de) 2007-03-26 2011-10-26 Dako Denmark A/S Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
ES2579323T3 (es) 2007-07-16 2016-08-09 Genentech, Inc. Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
KR101622412B1 (ko) * 2007-10-19 2016-05-18 제넨테크, 인크. 시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
CL2009000062A1 (es) * 2008-01-31 2010-05-14 Genentech Inc Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas.
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
EP2409155A1 (de) 2009-03-15 2012-01-25 Technion Research and Development Foundation, Ltd. Lösliche hla-komplexe zur verwendung bei der krankheitsdiagnose
US8362213B2 (en) 2009-04-01 2013-01-29 Genentech, Inc. Anti-FcRH5 antibodies and immunoconjugates and methods of use
PE20120878A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
TWI507524B (zh) 2009-11-30 2015-11-11 Genentech Inc 診斷及治療腫瘤之組合物及方法
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
DK3736292T3 (da) 2013-12-17 2024-07-22 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
EP3689910A3 (de) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Verfahren zur verwendung von anti-cd79b-immunkonjugaten
AR105026A1 (es) 2015-06-16 2017-08-30 Genentech Inc ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3497121A2 (de) * 2016-08-11 2019-06-19 Kite Pharma Eu B.V. Verfahren zur herstellung und verwendung von löslichen mhc-molekülen
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3719033A1 (de) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilisiertes mhc i
WO2021007338A1 (en) 2019-07-08 2021-01-14 Imcare Biotech, Llc. Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
US20240043512A1 (en) 2019-09-11 2024-02-08 Imcare Biotech, Llc Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
JP2023507120A (ja) 2019-12-18 2023-02-21 テネオフォー， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000160A1 (en) 1977-09-28 1979-04-05 Nat Res Dev Improvements in or relating to immunological preparations
US4400376A (en) 1979-03-27 1983-08-23 National Research Development Corporation Immunological preparations
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5130297A (en) 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells

Also Published As

Publication number Publication date
WO1999011775A1 (en) 1999-03-11
EP1017799A4 (de) 2004-08-04
DE69833949T2 (de) 2007-02-22
US6248564B1 (en) 2001-06-19
EP1017799A1 (de) 2000-07-12
EP1017799B1 (de) 2006-03-22
DE69833949D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
ATE321131T1 (de) Mutierte klasse-i-mhc-moleküle
DE60010098D1 (de) 28-epirapaloge
MY108864A (en) Peptide-carbohydrate conjugates generating t-cell immunity
DE59903442D1 (de) Azidfreie, gaserzeugende Zusammensetzung
CY1117235T1 (el) Νεϊσσεριακες συνθεσεις συνδυασμου
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
DE69730202D1 (de) Azidfreie, gaserzeugende zusammensetzungen
CY1106789T1 (el) Γενικος φορεας για στοχευση μοριων σε κυτταρα που εκφραζουν gb3 υποδοχεα
PT996668E (pt) Composicoes aquosas termofixas
DE122004000025I2 (de) Borons{ure-und-esterverbindungen, deren Systhese und Verwendungen
SE9702773D0 (sv) Novel compounds
DK1404377T3 (da) Forbedrede chelatorkonjugater
GB9717905D0 (en) Lipid-containing compositions and uses thereof
BG107220A (en) Antitumoral ecteinascudin derivatives
ES2175734T3 (es) Composiciones de lavado y de acondicionamiento a base de silicona y de goma de galactomanano hidrofoba.
CY1108526T1 (el) Εμβολια εναντι καρκινων
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
DE19981911T1 (de) Gasbildende Zusammensetzung
DE59902827D1 (de) Azidfreie, gaserzeugende Zusammensetzung
TR200201683T2 (tr) İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları
NO20031860D0 (no) Kahalaolid F
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
DE50010265D1 (de) Azidfreie gaserzeugende Zusammensetzung
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties